Literature DB >> 8858472

A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project.

D Felmingham1, R N Grüneberg.   

Abstract

The Alexander Project is a unique, international, collaborative antimicrobial susceptibility surveillance study of bacterial pathogens causing community-acquired lower respiratory tract infection. Fifteen centres, ten in the European Union (EU) and five in the USA, each submitted up to 400 isolated per year for 2 years (1992 and 1993) to a central laboratory for re-identification and determination of MICs of 15 antimicrobials using the Sensititre microbroth incorporation technique. Of the total of 6385 isolates collected, Haemophilus influenzae (2718), Streptococcus pneumoniae (1856) and Moraxella catarrhalis (818) were the most frequently identified pathogens. Staphylococcus aureus (690). Haemophilus parainfluenzae (183) and Klebsiella pneumoniae (120) were identified less commonly. High-level penicillin resistance in S. pneumoniae (MIC > or = 2 mg/L) was found in 222 isolates, an overall prevalence of 12% which varied from < 1% in Germany, Italy, UK and two of the five USA centres, to 3.8-40.4% in the remainder, with the highest prevalence found in France and Spain. Intermediate penicillin resistance (MIC 0.12-1 mg/L) was identified in 228 isolates of S. pneumoniae, an overall prevalence of 12.3%, with individual centre prevalence varying widely (EU, 0-52.3%; USA, 0-20.9%) and not always following that of high-level resistance. Resistance to other, unrelated, antimicrobials, except notably the fluoroquinolones, was strongly associated with beta-lactam resistance. beta-lactamase production was detected in 492 isolates of H. influenzae, an overall prevalence of 18.1%. Rates of detection varied widely between centres from 1.4% in Weingarten, Germany in 1993 to 38.5% in Barcelona, Spain in 1992. In general, the prevalence of beta-lactamase production was higher and less variable in USA centres than in those of the EU. beta-Lactamase was detected consistently in the majority of isolates of M. catarrhalis with an overall prevalence of 81.7%. Virtually no other resistance phenotype was recognised in this species. Of the 690 collected, most isolates of S. aureus produced beta-lactamase with rates of detection varying from 52.2%-89.1%. Isolates from two centres, Genoa, Italy in 1992 and Paris, France in 1993, were associated with a high prevalence of methicillin-resistance (34.8% and 43.8%, respectively). Combined isolates of H. parainfluenzae and K. pneumoniae accounted for only 4.7% of the total collection. Although the current data are insufficient to allow analysis of trends in resistance, the study participants have continued to collect further isolates in 1994 and 1995 which will be reported in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858472     DOI: 10.1093/jac/38.suppl_a.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection.

Authors:  George G. Zhanel
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

4.  Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.

Authors:  G Woodnutt; V Berry
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Surveillance of antimicrobial resistance. Centralised surveys to validate routine data offer a practical approach.

Authors:  D M Livermore; A P Macgowan; M C Wale
Journal:  BMJ       Date:  1998-09-05

6.  Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

Authors:  D J Hoban; A K Wierzbowski; K Nichol; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Pulmonary thin-section CT findings in acute Moraxella catarrhalis pulmonary infection.

Authors:  F Okada; Y Ando; T Nakayama; S Tanoue; R Ishii; A Ono; M Watanabe; H Takaki; T Maeda; H Mori
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

Review 8.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine.

Authors:  Paola Marchisio; Susanna Esposito; Gian Carlo Schito; Anna Marchese; Roberta Cavagna; Nicola Principi
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

10.  Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.

Authors:  Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-05-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.